| Place of Origin: | China |
| Brand Name: | Center Enamel |
| Certification: | ISO 9001,CE, NSF/ANSI 61, WRAS, ISO 28765, LFGB, BSCI, ISO 45001 |
| Minimum Order Quantity: | 1 Sets |
| Price: | 2000 |
| Delivery Time: | 2 months |
| Payment Terms: | L/C,T/T |
| Supply Ability: | 200 sets / days |
|
Detail Information |
|||
What Is a Pharma Reactor? GMP Design, Types & Applications
Answering the core question: What is a pharma reactor, and what design features distinguish it from a standard chemical reactor? A pharma reactor is a GMP-compliant pressure vessel engineered with sanitary design principles to manufacture active pharmaceutical ingredients (APIs) and intermediates under conditions that ensure product purity, batch traceability, and validated cleanability. Key distinguishing features include internal surface roughness (Ra) below 0.4-0.8 micrometers to prevent product adhesion and enable effective clean-in-place (CIP), zero-dead-leg piping and sanitary clamp connections to eliminate contamination traps, integrated sterilize-in-place (SIP) capability for biopharmaceutical applications, full material traceability with 3.1B certificates per EN 10204, and instrumentation qualified through Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) protocols per ISPE Baseline Guides.
1. Core GMP Design Principles for Pharma Reactors
2. Major Types of Pharma Reactors
Pharma Reactor Types Comparison Matrix
| Reactor Type | Construction Material | Volume Range | Primary GMP Application |
|---|---|---|---|
| Stainless Steel API Reactor | 316L, electropolished | 500 - 10,000 L | Small molecule API synthesis |
| Single-Use Bioreactor (SUB) | Disposable polymer film | 50 - 2,000 L | Mammalian cell culture, microbial fermentation |
| Glass-Lined Pharma Reactor | Glass-lined carbon steel | 100 - 8,000 L | Corrosive API steps (halogenation, nitration) |
Frequently Asked Questions (FAQ)
Q: What is the primary function of a pharma reactor?
A: A pharma reactor manufactures active pharmaceutical ingredients and intermediates under cGMP conditions, with sanitary design features (Ra < 0.4 micrometers, zero dead legs, CIP/SIP capability) that ensure product purity, batch traceability, and validated cleanability per FDA, EMA, and ICH guidelines.
Q: What is CIP and why is it critical for pharma reactors?
A: Clean-in-Place (CIP) is an automated cleaning system that circulates alkaline, acidic, and rinse solutions through spray balls to achieve validated residue levels (typically < 10 ppm TOC) without disassembling the reactor; it eliminates cross-contamination between batches and products, which is mandatory for multi-product pharmaceutical manufacturing.
Q: How are pharma reactors validated?
A: Validation follows the IQ/OQ/PQ protocol: Installation Qualification verifies that the equipment is installed per design specifications, Operational Qualification confirms that the reactor operates within all design parameters across the full range, and Performance Qualification demonstrates that the reactor consistently produces product meeting pre-defined critical quality attributes under actual process conditions.
Q: What material surface finish is required for pharma reactors?
A: Per ASME-BPE and 3-A sanitary standards, product-contact surfaces must be electropolished to Ra below 0.4-0.8 micrometers, with all welds fully penetrated and passivated to remove free iron and restore the chromium oxide passive layer, preventing microbial retention and enabling effective CIP cleaning.